SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Vaz Frédéric M.)
 

Search: WFRF:(Vaz Frédéric M.) > (2023) > Effect of β2-agonis...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Effect of β2-agonist treatment on insulin-stimulated peripheral glucose disposal in healthy men in a randomised placebo-controlled trial

van Beek, Sten M. M. (author)
Bruls, Yvonne M. H. (author)
Vanweert, Froukje (author)
show more...
Fealy, Ciarán E. (author)
Connell, Niels J. (author)
Schaart, Gert (author)
Moonen-Kornips, Esther (author)
Jörgensen, Johanna A. (author)
Vaz, Frédéric M. (author)
Smeets, Ellen T. H. C. (author)
Joris, Peter J. (author)
Gemmink, Anne (author)
Houtkooper, Riekelt H. (author)
Hesselink, Matthijs K. C. (author)
Bengtsson, Tore, 1970- (author)
Stockholms universitet,Institutionen för molekylär biovetenskap, Wenner-Grens institut
Havekes, Bas (author)
Schrauwen, Patrick (author)
Hoeks, Joris (author)
show less...
 (creator_code:org_t)
2023-01-12
2023
English.
In: Nature Communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 14
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • β2-agonist treatment improves skeletal muscle glucose uptake and whole-body glucose homeostasis in rodents, likely via mTORC2-mediated signalling. However, human data on this topic is virtually absent. We here investigate the effects of two-weeks treatment with the β2-agonist clenbuterol (40 µg/day) on glucose control as well as energy- and substrate metabolism in healthy young men (age: 18-30 years, BMI: 20-25 kg/m2) in a randomised, placebo-controlled, double-blinded, cross-over study (ClinicalTrials.gov-identifier: NCT03800290). Randomisation occurred by controlled randomisation and the final allocation sequence was seven (period 1: clenbuterol, period 2: placebo) to four (period 1: placebo, period 2: clenbuterol). The primary and secondary outcome were peripheral insulin-stimulated glucose disposal and skeletal muscle GLUT4 translocation, respectively. Primary analyses were performed on eleven participants. No serious adverse events were reported. The study was performed at Maastricht University, Maastricht, The Netherlands, between August 2019 and April 2021. Clenbuterol treatment improved peripheral insulin-stimulated glucose disposal by 13% (46.6 ± 3.5 versus 41.2 ± 2.7 µmol/kg/min, p = 0.032), whereas skeletal muscle GLUT4 translocation assessed in overnight fasted muscle biopsies remained unaffected. These results highlight the potential of β2-agonist treatment in improving skeletal muscle glucose uptake and underscore the therapeutic value of this pathway for the treatment of type 2 diabetes. However, given the well-known (cardiovascular) side-effects of systemic β2-agonist treatment, further exploration on the underlying mechanisms is needed to identify viable therapeutic targets.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view